Applies to methyltestosterone: oral capsules, oral tablets.
Side effects include:
Males: Gynecomastia, frequent or persistent penile erections.
Females: Amenorrhea, other menstrual irregularities, inhibition of gonadotropin secretion, virilization (e.g., deepening of the voice, clitoral enlargement).
For Healthcare Professionals
Applies to methyltestosterone: compounding powder, oral capsule, oral tablet.
General
The more commonly reported adverse effects of androgen therapy in males is gynecomastia and excessive frequency and duration of penile erections; in women, virilization including voice deepening and clitoral enlargement.[Ref]
Cardiovascular
Frequency not reported: Edema with or without congestive heart failure, myocardial infarction, stroke
Postmarketing reports: venous thromboembolic events, including deep vein thrombosis (DVT)[Ref]
Endocrine
Frequency not reported: Gynecomastia, virilization (women), hirsutism[Ref]
Hepatic
Rare (less than 0.1%): Peliosis hepatic
Frequency not reported: Cholestatic jaundice, altered liver function[Ref]
Genitourinary
Frequency not reported: Amenorrhea, menstrual irregularities, excessive frequency and duration of penile erections, oligospermia, increased or decreased libido[Ref]
Metabolic
Frequency not reported: Retention of sodium, chloride, water, potassium, calcium and inorganic phosphates, increased serum cholesterol, hypercalcemia[Ref]
Dermatologic
Frequency not reported: Male pattern baldness, acne[Ref]
Gastrointestinal
Frequency not reported: Nausea, vomiting[Ref]
Musculoskeletal
Frequency not reported: acceleration of bone maturation without producing compensatory gain in linear growth resulting in compromised adult stature[Ref]
Hematologic
Frequency not reported: Suppression of clotting factors II, V, VII, and X; bleeding (in patients on concomitant anticoagulant therapy and polycythemia)[Ref]
Hypersensitivity
Very rare (less than 0.01%): Anaphylactoid reactions[Ref]
Nervous system
Frequency not reported: Headache, generalized paresthesia[Ref]
Oncologic
Rare (less than 0.1%): Hepatocellular neoplasms[Ref]
Respiratory
Postmarketing reports: venous thromboembolic events, including pulmonary embolism[Ref]
Psychiatric
Frequency not reported: Steroid abuse, anxiety, depression